OLFML3 and colorectal carcinoma: To determine whether OLFML3 expression in CRC is modulated by anti-VEGF therapy, we analyzed tumors from CRC patients treated (or not) with the anti-VEGF-A antibody bevacizumab (Avastin) [33].